Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 3
1977 8
1978 3
1979 2
1980 1
1981 1
1982 10
1983 3
1984 2
1985 2
1986 5
1987 2
1988 3
1989 5
1990 4
1991 10
1992 20
1993 20
1994 20
1995 21
1996 32
1997 30
1998 37
1999 50
2000 56
2001 44
2002 58
2003 107
2004 121
2005 158
2006 184
2007 184
2008 196
2009 199
2010 205
2011 227
2012 266
2013 269
2014 263
2015 270
2016 245
2017 259
2018 248
2019 259
2020 255
2021 247
2022 235
2023 231
2024 250
2025 271
2026 159

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,173 results

Results by year

Filters applied: . Clear all
Page 1
Mechanism of action of memantine.
Johnson JW, Kotermanski SE. Johnson JW, et al. Curr Opin Pharmacol. 2006 Feb;6(1):61-7. doi: 10.1016/j.coph.2005.09.007. Epub 2005 Dec 20. Curr Opin Pharmacol. 2006. PMID: 16368266 Review.
Memantine is a clinically useful drug in many neurological disorders, including Alzheimer's disease. ...These potentially important differences between memantine and ketamine include effects on gating of blocked channels and binding of memantine to two sites …
Memantine is a clinically useful drug in many neurological disorders, including Alzheimer's disease. ...These potentially important d …
Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.
Balázs N, Bereczki D, Kovács T. Balázs N, et al. Ideggyogy Sz. 2021 Nov 30;74(11-12):379-387. doi: 10.18071/isz.74.0379. Ideggyogy Sz. 2021. PMID: 34856086 Free article. Review. English.
Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available symptomatic treatments. Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer's therapy for approximately t …
Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available …
Memantine.
Jarvis B, Figgitt DP. Jarvis B, et al. Drugs Aging. 2003;20(6):465-76; discussion 477-8. doi: 10.2165/00002512-200320060-00005. Drugs Aging. 2003. PMID: 12710865 Review.
Memantine, an uncompetitive antagonist with moderate affinity for NMDA receptors, demonstrates voltage-dependency and relatively fast on/off receptor kinetics. ...Memantine 10 mg/day improved measures of dementia in care-dependent inpatients with Alzheimer's disease …
Memantine, an uncompetitive antagonist with moderate affinity for NMDA receptors, demonstrates voltage-dependency and relatively fast …
Memantine. Merz.
Kilpatrick GJ, Tilbrook GS. Kilpatrick GJ, et al. Curr Opin Investig Drugs. 2002 May;3(5):798-806. Curr Opin Investig Drugs. 2002. PMID: 12090556 Review.
In February 2002, the CPMP recommended to the EU commission to approve memantine for the treatment of moderately severe-to-severe Alzheimer's disease. At this time, marketing authorization was expected late in the first half of 2002, and Lundbeck planned to launch meman …
In February 2002, the CPMP recommended to the EU commission to approve memantine for the treatment of moderately severe-to-severe Alz …
Memantine for dementia.
Areosa Sastre A, McShane R, Sherriff F. Areosa Sastre A, et al. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003154. doi: 10.1002/14651858.CD003154.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154. doi: 10.1002/14651858.CD003154.pub3. PMID: 15495043 Updated.
OBJECTIVES: To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, or vascular or mixed dementia. SEARCH STRATEGY: Trials were identified from a search of the Trial-based Specialized Register of the Cochrane Dementia and Cognitive I …
OBJECTIVES: To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, or vascular or mixed deme …
Memantine-induced myoclonus.
Kitagawa N, Takeuchi A. Kitagawa N, et al. Neurology. 2014 Oct 7;83(15):1387. doi: 10.1212/WNL.0000000000000863. Neurology. 2014. PMID: 25288698 No abstract available.
I remember.
Ladouceur R. Ladouceur R. Can Fam Physician. 2006 Feb;52:155. Can Fam Physician. 2006. PMID: 16529383 Free article. English, French. No abstract available.
Classics in Chemical Neuroscience: Memantine.
Alam S, Lingenfelter KS, Bender AM, Lindsley CW. Alam S, et al. ACS Chem Neurosci. 2017 Sep 20;8(9):1823-1829. doi: 10.1021/acschemneuro.7b00270. Epub 2017 Aug 9. ACS Chem Neurosci. 2017. PMID: 28737885 Review.
Since its approval by the FDA in 2003, memantine, alone and in combination with donepezil, has improved patient outcomes in terms of cognition, behavioral disturbances, daily functioning, and delaying time to institutionalization. In this review, we will highlight the hist …
Since its approval by the FDA in 2003, memantine, alone and in combination with donepezil, has improved patient outcomes in terms of …
Memantine hydrochloride.
Witt A, Macdonald N, Kirkpatrick P. Witt A, et al. Nat Rev Drug Discov. 2004 Feb;3(2):109-10. doi: 10.1038/nrd1311. Nat Rev Drug Discov. 2004. PMID: 15040575 No abstract available.
[Memantine].
Molinuevo JL. Molinuevo JL. Neurologia. 2003 Jun;18(5):255-61. Neurologia. 2003. PMID: 12768511 Review. Spanish.
N-methyl-D-aspartate (NMDA) receptor antagonists have very extensive therapeutic potential in several central nervous system disorders and can be used as neuroprotective treatment in chronic neurodegenerative diseases and as symptomatic treatment in other neurologic diseases as e …
N-methyl-D-aspartate (NMDA) receptor antagonists have very extensive therapeutic potential in several central nervous system disorders and c …
5,173 results